Zymeworks licences DLL3-targeted cancer drug ZW209 to Roche in deal worth up to $813M
What happened: Zymeworks has entered an exclusive global licence and collaboration agreement with Roche to develop and commercialise ZW209, an investigational cancer immunotherapy, announced on 23 October 2026. Zymeworks will receive a $55 million upfront payment and a further $40 million when Roche initiates the Phase 1b trial, plus up to $718 million in development, commercial and sales-based milestone payments and tiered high-single-digit to mid-teen royalties on future net sales of any approved medicines.
Why it matters: ZW209 is a trispecific T cell engager designed to treat small cell lung cancer and other DLL3-expressing neuroendocrine tumours. It works by binding to DLL3, a protein on the surface of tumour cells, while simultaneously engaging two distinct signals on killer T cells (CD3 and CD28), aiming to produce a stronger and more durable immune attack on the cancer. It was designed using Zymeworks' Azymetric and EFECT antibody platforms.
Next steps: ZW209 has US FDA Investigational New Drug clearance and an open-label, global Phase 1 study is under way. Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche (which will fund it); Roche then takes over global development and commercialisation.
Read more: Zymeworks Inc., 23 October 2026 · Reuters, 23 October 2026